Tesamorelin research and evidence overview

Tesamorelin is the rare peptide in this catalogue with an unambiguous answer: it is FDA-approved, marketed as Egrifta, and it reduced visceral fat in randomized placebo-controlled trials in more than 800 adults. The important caveats are equally concrete and come from the label itself — long-term cardiovascular safety has not been established, and it is explicitly not a weight-loss drug. Almost every popular claim about tesamorelin for body recomposition in healthy people sits outside the studied population.

The approval rests on two multicentre, double-blind, placebo-controlled phase 3 trials in adults on antiretroviral therapy with excess abdominal fat, pooled by Falutz and colleagues in the Journal of Clinical Endocrinology and Metabolism (2010). 806 patients were randomized 2:1 to tesamorelin 2 mg daily subcutaneously (n=543) or placebo (n=263) for 26 weeks, then re-randomized for a 26-week extension (PubMed 20554713).

At week 26, visceral adipose tissue measured by CT fell by 24 ± 41 cm² with tesamorelin versus a 2 ± 35 cm² increase on placebo — a treatment effect of −15.4% (P<0.001). Abdominal subcutaneous fat did not change significantly, which is the clinically relevant point in lipodystrophy. Triglycerides fell (treatment effect −12.3%) as did the cholesterol/HDL ratio (−7.2%), IGF-1 rose by 108 ± 112 ng/mL, and patient and physician ratings of abdominal appearance improved. Reductions were maintained at week 52 in patients who stayed on drug.

The companion 404-patient trial reported the same pattern and one detail that matters for anyone considering the drug long term: visceral fat fell about 18% over 12 months of continued treatment, and the gains made in the first six months were rapidly lost in patients switched from tesamorelin to placebo (Falutz et al., JAIDS 2010). The effect requires continued dosing.

A pre-specified per-protocol analysis of 402 tesamorelin-treated participants defined responders as those with at least 8% VAT reduction and compared them with non-responders across 52 weeks (Stanley et al., Clinical Infectious Diseases, 2012). Responders showed greater triglyceride reductions and attenuated changes in fasting glucose and HbA1c, with changes in lipids and glucose homeostasis significantly associated with percentage change in VAT.

Read the direction carefully: non-responders' glucose and HbA1c drifted upward. Growth-hormone-axis stimulation carries a glucose cost, which is why the label lists glucose intolerance and diabetes among its warnings — 5% of treated patients versus 1% on placebo developed elevated HbA1c.

Egrifta is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. The label's limitations of use state that long-term cardiovascular safety has not been established, that it is not indicated for weight-loss management (the effect is weight-neutral), and that there are no data supporting improved antiretroviral compliance. Warnings cover increased risk of neoplasms, elevated IGF-1 requiring monitoring, fluid retention with arthralgia and carpal tunnel syndrome, hypersensitivity reactions (4%), injection-site reactions (25% vs 14% on placebo), and increased mortality in critical illness (EGRIFTA WR prescribing information, DailyMed).

• The trial population was adults with HIV-associated lipodystrophy on antiretroviral therapy — a specific metabolic state, not the general public.
• The endpoint was CT-measured visceral fat, not scale weight, muscle mass, or longevity.
• Benefit disappears on discontinuation, so the relevant safety question is long-term exposure — which the label says is unestablished for cardiovascular outcomes.
• Compounded or research-grade tesamorelin is not the approved product and carries no assurance of identity, sterility, or potency.